Home > Compound List > Product Information
Dimercaprol_Molecular_structure_CAS_59-52-9)
Click picture or here to close

Dimercaprol

Catalog No. DB06782 Name DrugBank
CAS Number 59-52-9 Website http://www.ualberta.ca/
M. F. C3H8OS2 Telephone (780) 492-3111
M. W. 124.22502 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 4478

SYNONYMS

IUPAC name
2,3-disulfanylpropan-1-ol
IUPAC Traditional name
BAL
Brand Name
Dimercaprol
Bal In Oil Injection
Synonyms
British Anti-Lewisite
BAL
2,3-Dimercaptopropanol
2,3-Dimercapro

DATABASE IDS

PubChem CID 3080
CAS Number 59-52-9
PubChem SID 99443293

PROPERTIES

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II. It was developed as an experimental antidote against the arsenic-based poison gas Lewisite. It has been used clinically since 1949 in arsenic, cadmium and mercury poisoning. In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper. Dimercaprol is a potentially toxic drug, and its use may be accompanied by multiple side effects.
Indication For the treatment of arsenic, gold and mercury poisoning. Indicated in acute lead poisoning when used concomitantly with edetate calcium disodium (DB00974).
Pharmacology Due to its oily nature, dimercaprol is not absorbed orally and its administration requires deep intra-muscular injection that is extremely painful and allergenic. It was found to mobilize and relocate lead to the brain, increasing its neurotoxic effects. Although treatment with dimercaprol increases the excretion of cadmium, there is a concomitant increase in renal cadmium concentration, so its use should be avoided in cases of cadmium toxicity.
Toxicity The intramuscular LD50 in rats is approximately 105 mg/kg; intraperitoneally 140 mg/kg. The intraperitoneal LD80 in mice is approximately 125 mg/kg. Dimercaprol has been shown in animal experiments to increase brain deposition of arsenite, organic mercury compounds and increase the toxicity of cadmium and lead. Dimercaprol has been shown to induce seizure in animal studies and also is nephrotoxic.
Absorption After intra-muscular injection.
Half Life The drug has a short half life.
Elimination Urine.
References
Walshe JM: The conquest of Wilson's disease. Brain. 2009 Aug;132(Pt 8):2289-95. Epub 2009 Jul 13. [Pubmed]
Boscolo M, Antonucci S, Volpe AR, Carmignani M, Di Gioacchino M: Acute mercury intoxication and use of chelating agents. J Biol Regul Homeost Agents. 2009 Oct-Dec;23(4):217-23. [Pubmed]
Flora SJ, Pachauri V: Chelation in metal intoxication. Int J Environ Res Public Health. 2010 Jul;7(7):2745-88. Epub 2010 Jun 28. [Pubmed]
Andersen O: Chemical and biological considerations in the treatment of metal intoxications by chelating agents. Mini Rev Med Chem. 2004 Jan;4(1):11-21. [Pubmed]
External Links
Wikipedia

REFERENCES

  • Walshe JM: The conquest of Wilson's disease. Brain. 2009 Aug;132(Pt 8):2289-95. Epub 2009 Jul 13. Pubmed
  • Boscolo M, Antonucci S, Volpe AR, Carmignani M, Di Gioacchino M: Acute mercury intoxication and use of chelating agents. J Biol Regul Homeost Agents. 2009 Oct-Dec;23(4):217-23. Pubmed
  • Flora SJ, Pachauri V: Chelation in metal intoxication. Int J Environ Res Public Health. 2010 Jul;7(7):2745-88. Epub 2010 Jun 28. Pubmed
  • Andersen O: Chemical and biological considerations in the treatment of metal intoxications by chelating agents. Mini Rev Med Chem. 2004 Jan;4(1):11-21. Pubmed